The addition of enzalutamide to exemestane may improve the progression-free survival of a subset of patients with HR-positive, HER2-negative, advanced breast cancer, study data suggest.

Long-term follow-up data from the TEAM trial confirm the suitability of exemestane both as a monotherapy and sequentially after tamoxifen for the treatment of postmenopausal women with hormone receptor-positive early breast cancer.

In all, 83% of participants received fulvestrant and 17% were given exemestane.

The most commonly prescribed AI was letrozole (52.2%) followed by anastrozole (44.2%), and exemestane (3.6%), and the most used DOACs were rivaroxaban (53.2%) and apixaban (35.0%).

The co-primary endpoint of PFS in the overall trial population was significantly improved with elacestrant 400 mg/day versus physician’s choice of fulvestrant, anastrozole, letrozole, or exemestane, at a median of 2.8 and 1.9 months, respectively, and a hazard ratio (HR) for progression or death of 0.70 favoring the oral SERD.

The meta-analysis included data on 7030 premenopausal women included in the ABCSG 12, TEXT, SOFT, or HOBOE trials that compared an AI (anastrozole, exemestane, or letrozole) with tamoxifen, both given for 3–5 years, on a background of ovarian suppression with goserelin or triptorelin.

But there was no significant difference in median estradiol level changes between the patients given GnRHa with tamoxifen or exemestane.

There was also no difference between palbociclib plus endocrine therapy (exemestane or fulvestrant) and capecitabine in people with wild-type ESR1 from both cohorts, at a median of 8.0 and 10.6 months, respectively.

Around a third (31.3%) of these patients received tamoxifen, raloxifene, nonsteroidal AIs (anastrozole or letrozole), or a steroidal AI (exemestane), the researchers say in JAMA Network Open .

Supplementing exemestane with the selective histone deacetylase inhibitor chidamide significantly prolongs the progression-free survival of women with hormone receptor-positive, HER2-negative advanced breast cancer, phase III trial findings indicate.

Specifically, women with HER-2 positive disease derived significantly greater benefit from the addition of tamoxifen to ovarian suppression and less benefit from the addition of exemestane than did those with HER2-negative disease.

The majority of side effects did not differ between each of the aromatase inhibitors used, but gastrointestinal events were more common with exemestane than with letrozole, while hypercholesterolemia was more common with anastrozole and letrozole than with exemestane.

An inexpensive, commercially available dexamethasone mouthwash substantially reduces the incidence and severity of stomatitis in patients receiving everolimus and exemestane for breast cancer, US study data show.

. --- A post-hoc analysis of the phase III MA.27 trial , which compared adjuvant exemestane with anastrozole in postmenopausal women with hormone receptor-positive, early-stage breast cancer, shows that osteoporosis therapy is associated with improved event-free and distant disease-free survival.